This inventor holds 3 USPTO granted patents. Top assignees: Boston University, Symphogen A/s. Active years: 1998-2015.
Company Filing History:
Years Active: 1998-2015
Title: Celebrating the Innovations of Inventor Jacqueline Sharon
Introduction
Jacqueline Sharon, an accomplished inventor based in Chestnut Hill, MA, has made significant contributions to the field of biomedicine through her innovative work on recombinant polyclonal proteins. With a total of three patents to her name, her research focuses on enhancing therapeutic antibody formulations that have the potential to improve patient outcomes in various medical conditions.
Latest Patents
Jacqueline Sharon's latest patents include advanced methods for manufacturing recombinant polyclonal proteins. One notable invention is a method for producing a recombinant polyclonal antibody composition. This groundbreaking method involves obtaining a collection of cells transfected with a diverse library of nucleic acid sequences, allowing each cell to express a unique member of the polyclonal protein family. This innovation offers a superior replacement for traditional plasma-derived immunoglobulin products, significantly advancing therapeutic approaches.
Additionally, she has developed methods for creating and utilizing libraries of polyclonal antibodies targeting specific antigens. These libraries aim to treat and prevent a broad range of diseases, from cancers to infectious diseases, by utilizing customized protein samples tailored to individual patient needs. The overlapping innovations in her patents reflect a commitment to harnessing the power of biotechnology for therapeutic applications.
Career Highlights
Throughout her career, Jacqueline has collaborated with prominent institutions such as Boston University and Symphogen A/S, where she helped drive research and development efforts. Her work has gained recognition for its potential applications in disease treatment and diagnostics, paving the way for future improvements in the field of immunotherapy.
Collaborations
Jacqueline has worked alongside notable colleagues, including John S. Haurum and Finn C. Wiberg. These collaborations have brought together diverse expertise and have been instrumental in pushing forward innovative solutions in the biomedical research landscape.
Conclusion
Jacqueline Sharon stands out as a pioneering inventor in the field of recombinant proteins. Her inventive methodologies and collaborative spirit are driving forces in the development of advanced therapeutic options. As the field of biotechnology continues to evolve, her contributions are sure to leave a lasting impact, benefiting both the scientific community and patients in need of innovative treatments.